1 unknown. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Unknown 1 |
Follow Celcuity CELx HSF: new trials by email Literature Review of Celcuity CELx HSF trials Research Report on Celcuity CELx HSF
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling Doxorubicin, Cyclophosphamide, Weekly Paclitaxel - HER2-negative Breast Cancer | Phase 2 | Unknown | NSABP Foundation Inc | 64 | 2018-05-14 | 2023-03-06 |
Breast Neoplasms (1)
United States (1)